PUBLIC COMPANY
save$DERMJourney Medical Corp
$DERM6.5250-1.88%Scottsdale, AZ, USupdated 1h ago
community read0 votes
pipeline
4
marketed
4
phase 3
0
catalysts ytd
3
approvals ytd
1
recalls ytd
0
Pipeline(4)
pipeline depth4 products
4Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase2Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
- phase3A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- phase3A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
- phase1Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Apr 22, 26grantAlloush Ramsey · Chief Operating Officer46,863 sh
- Apr 22, 26grantAlloush Ramsey · Chief Operating Officer62,795 sh
- Apr 22, 26grantBenesch Joseph · CFO28,907 sh
- Apr 22, 26grantBenesch Joseph · CFO41,860 sh
- Apr 22, 26grantMaraoui Claude · President & CEO49,277 sh
- Apr 22, 26grantMaraoui Claude · President & CEO82,915 sh
🐶 Hiring Signal
News
- Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b missThe anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…biospace · 10d ago
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that